Parkinson's Disease

It is estimated that over one million Americans are affected by Parkinson's Disease. Recent research proposes that microvascular disorder hinders the blood flow to dopamine-producing neurons, thereby causing Parkinson's Disease. People with this condition might benefit form infusions of our treatment, which hopefully, could slow the progression of their disease or reverse the symptoms. Parkinson's Disease is an unmet medical need and Zhittya Genesis Medicine believes its drug treatment is a "disease modifying agent", which means if Zhittya is correct, the drug treatment should address the root cuaes of the disease and not just the symptoms.

Zhittya filed an IND with the USA FDA for the treatment of Parkinson's Disease in 2019 Feedback from the FDA was generally positive, but the agency requested an additional animal toxicity study, as this was the first time Zhittya's drug was being evaluated for a central nervous system disorder. The animal trial Zhittya proposed to the FDA has been accepted and after completion of that study Zhittya Genesis Medicine believes it will be on track to start its Phase I study in 2022.

This is our video on our in-depth theory on treating Parkinson's Disease with FGF-1.

Compassionate Use Clinical Trial